It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

GSK and Immunocore hope the TCRs can prove to ... inhibitors such as Merck’s Keytruda and BMS’ Opdivo, and the first CAR-T therapies from Novartis and Kite Pharma, anticipated to gain approval ...

After its market withdrawal in 2022, GSK’s multiple myeloma drug Blenrep ... new competition for J&J and Legend Biotech’s ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

It is worth considering GSK (GSK), which belongs to the Zacks Medical - Biomedical and Genetics industry. When looking at the last two reports, this drug developer has recorded a strong streak of ...